MariTide’s Phase 2 press release “underwhelms” with 20% weight loss from Cohort A and 17% weight loss from Cohort B at 52-weeks, with it being unclear if these are placebo adjusted. MariTide’s weight ...

Amgen (AMGN) reported today the highly anticipated results of a mid-stage trial of its experimental weight loss drug and ...

Amgen stock crashed Tuesday after its weight-loss drug met Wall Street's expectations, but was only on par with Eli Lilly's ...

Amgen's experimental drug MariTide helped overweight or obese patients shed up to 20% of their body weight in a mid-stage ...

The pharmaceutical manufacturer Amgen announced on Tuesday that an experimental obesity drug helped patients lose up to 20 ...

Amgen Inc. announced on Tuesday that its experimental weight-loss drug, MariTide, demonstrated an average weight reduction of ...

A highly anticipated obesity-drug candidate from biotech Amgen helped patients shed a significant amount of weight in a ...

The S&P 500 and Nasdaq gained as tech stocks rebounded. Investors analyzed Trump's proposed tariffs, impacting the auto ...

The S&P 500 and Nasdaq Composite rose on Tuesday as investors assessed the threat of new tariffs from President-elect Donald ...

U.S. equities were mixed at midday following comments from President-elect Trump about new tariffs on Chinese, Canadian, and ...

Shares in Amgen fell by double digits Tuesday on long-awaited results for the company’s monthly MariTide shot, which is ...

The 30-stock Dow popped roughly 440 points, or about 1%, to a new record close during regular trading. The S&P 500 gained 0.3 ...